NHS 📈 Neuberger Berman High - Overview
Exchange: NYSE MKT • Country: USA • Currency: USD • Type: Fund • ISIN: US64128C1062 • High Yield Bond
NHS: Bonds, Loans, Credit, Investments
Additional Sources for NHS Fund
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NHS Fund Overview
| Market Cap in USD | 207m |
| Style | High Yield Bond |
| TER | 2.55% |
| IPO / Inception | 2003-07-28 |
NHS Fund Ratings
| Growth 5y | 29.2% |
| Fundamental | - |
| Dividend | 75.2% |
| Rel. Strength Industry | 292 |
| Analysts | - |
| Fair Price Momentum | 7.67 USD |
| Fair Price DCF | - |
NHS Dividends
| Dividend Yield 12m | 14.42% |
| Yield on Cost 5y | 16.84% |
| Annual Growth 5y | 1.93% |
| Payout Consistency | 92.6% |
NHS Growth Ratios
| Growth Correlation 3m | -86.4% |
| Growth Correlation 12m | 90.6% |
| Growth Correlation 5y | 28.3% |
| CAGR 5y | 3.13% |
| CAGR/Mean DD 5y | 0.24 |
| Sharpe Ratio 12m | 0.81 |
| Alpha | -8.93 |
| Beta | 0.86 |
| Volatility | 13.51% |
| Current Volume | 186.3k |
| Average Volume 20d | 143.2k |
What is the price of NHS stocks?
As of December 22, 2024, the stock is trading at USD 7.53 with a total of 186,305 shares traded.
Over the past week, the price has changed by -3.08%, over one month by -0.42%, over three months by -5.67% and over the past year by +14.70%.
As of December 22, 2024, the stock is trading at USD 7.53 with a total of 186,305 shares traded.
Over the past week, the price has changed by -3.08%, over one month by -0.42%, over three months by -5.67% and over the past year by +14.70%.
Is Neuberger Berman High a good stock to buy?
Neither. Based on ValueRay Analyses, Neuberger Berman High is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 29.21 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NHS as of December 2024 is 7.67. This means that NHS is currently overvalued and has a potential downside of 1.86%.
Neither. Based on ValueRay Analyses, Neuberger Berman High is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 29.21 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NHS as of December 2024 is 7.67. This means that NHS is currently overvalued and has a potential downside of 1.86%.
Is NHS a buy, sell or hold?
Neuberger Berman High has no consensus analysts rating.
Neuberger Berman High has no consensus analysts rating.
What are the forecast for NHS stock price target?
According to ValueRays Forecast Model, NHS Neuberger Berman High will be worth about 8.5 in December 2025. The stock is currently trading at 7.53. This means that the stock has a potential upside of +12.75%.
According to ValueRays Forecast Model, NHS Neuberger Berman High will be worth about 8.5 in December 2025. The stock is currently trading at 7.53. This means that the stock has a potential upside of +12.75%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 8.5 | 12.7% |